- Crane had a rough end to the fourth quarter, with a 21% drop in organic revenue and operating income that missed expectation by 12%.
- Fluid Handling beat expectations on revenue but missed on margins; orders were up sequentially, and key markets like chemicals and pharma are looking healthier.
- Aero is going to need more time; management expects a double-digit decline in commercial aero sales in '21, and the recovery here is probably a '22/'23 story.
- Crane will lag shorter-cycle industrial names in 2021 in terms of growth, but the valuation more than reflects that, and these shares look undervalued as a longer cycle recovery play.
For further details see:
Crane Has Cycle And Performance Challenges, But Looks Undervalued